<DOC>
	<DOCNO>NCT01009970</DOCNO>
	<brief_summary>This multicenter study phase II , open-label cardiopathic patient affect Non-Hodgkin 's lymphoma diffuse large B cell CD20 + grade IIIb follicular . The purpose study feasibility R-COMP cohort patient .</brief_summary>
	<brief_title>Study With Rituximab , Cyclophosphamide , Doxorubicin Liposomal ( MyocetÂ® ) , Vincristine , Prednisone , ( R-COMP ) Treat Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>NHL histological diagnosis diffuse large B cell CD20 + ( de novo shift lowgrade NHL pretreated ) , grade IIIb follicular NHL ; Age &gt; = 18 year ; Presence least 1 factor defines cardiopathy ; Life expectancy &gt; 3 month ; In case woman childbearing age absence pregnancy begin chemotherapy ; Written inform consent . Histology different NHL diffuse large cell CD20 + follicular IIIb Age &lt; 18 year Inability sign inform consent ; HIV positivity ; Patients HBsAg positive ; AST/ALT &gt; 2 time standard ; Bilirubin &gt; 2 time standard ; Creatinine &gt; 2.5 mg / dl ; Location CNS disease ; Pregnancy ongoing ; Damage organ medical problem could interfere therapy ; Current uncontrolled infection ; Senile dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
</DOC>